New York & Beijing, August 22, 2007 – Elsevier, the world’s largest provider of scientific, technical and medical information, has appointed NeoTrident Technology Ltd. as its sales agent for the corporate market in China. Under a prior strategic partnership with chemical information and management systems provider, Elsevier MDL, NeoTrident has been providing sales and support for a portfolio of products and software solutions including PharmaPendium and the CrossFire Databases (Beilstein, Gmelin and the Patent Chemistry Database). This new agreement expands representation to include Elsevier’s flagship products, ScienceDirect and Scopus, already widely used by China’s universities and research institutes supported directly by Elsevier’s own sales team.
“We are pleased to expand our relationship with NeoTrident, which has been extremely successful in its representation of Elsevier MDL to the pharmaceutical and biotechnology industries and CROs (Contract Research Organizations) throughout China,” stated Peter Katz, Senior Vice President, Corporate Sales, Elsevier. “NeoTrident is well positioned to support sales of ScienceDirect and Scopus to the corporate market throughout China because of its local market knowledge, network of contacts across numerous industries and scientific subject matter expertise. Working in close collaboration with our office in Beijing, NeoTrident will act as Sales Agent, providing what we anticipate will be outstanding Elsevier product representation and product training in China to a fast-growing set of customers – R&D-focused enterprises. In addition to plans to represent our products in numerous regional trade shows and conferences, NeoTrident also hosts an annual Users Group meeting, attracting many researchers and scientific professionals from around the country.”
Among the Elsevier products now represented by NeoTrident are:
ScienceDirect: Contains over 25% of the world's science, technology and medicine full text. This easy-to-use electronic platform of Elsevier publications contains more than eight million full-text articles from some of the most prestigious journal titles in the world as well as thousands of books.
Scopus: The largest abstract and citation database of peer-reviewed literature and quality web sources with smart tools to track, analyze and visualize research. It covers 15,000 journals in Science, Technology, Medicine and Social Sciences from more than 4,000 international publishers and contains over 30 million records with new content added daily.
PharmaPendium: A unique online resource that puts drug safety data of US- approved drugs at a researcher's fingertips. This information repository lets researchers understand the full scope of projected risks early in the drug development process.
CrossFire Databases: The world's largest compilation of chemical facts. As the cornerstone databases to organic and inorganic chemistry, the CrossFire Databases cover chemistry from 1771 to the present. They contain 15 million compounds, 15 million reactions and 500 million experimental properties for compounds and reactions. It also provides over one million original author abstracts from 1980-present, as well as pharmacological and eco-toxicological data describing the bioactivity of organic chemicals. CrossFire Beilstein, now Elsevier owned, covers organic chemistry mostly from journal articles while the Patent Chemistry Database covers organic chemistry found in patent documents; CrossFire Gmelin covers inorganic and organometallic compounds.
Elsevier’s long-time lead salesperson for corporate markets in China, Zhong Sixuan, commented, “Expanding our partnership with NeoTrident will help us rapidly increase the access of corporate customers to Elsevier products, especially in the fast-growing area of pharmaceutical research. ScienceDirect and Scopus are essential to R&D in many other sectors as well, so the scope of the opportunity makes it a good time to bring in NeoTrident to help Elsevier better serve the China corporate sector as it invests in the research tools needed to support world-class innovations.”